Amylin, India's Biocon Join Hands For Peptide-Based Diabetes Compound
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Biocon, India's largest biotech with products ranging from insulins to monoclonal antibodies and Amylin - developers of insulin injection Byetta (exanetide) - have agreed to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes
You may also be interested in...
BMS, Biocon Team Up To Rekindle Oral Insulin Hopes
After faltering last year with clinical development of its oral insulin, Biocon’s long hunt for a partner ends with Bristol-Myers Squibb, which signed a carefully worded “exclusive option agreement.”
BMS, Biocon Team Up To Rekindle Oral Insulin Hopes
After faltering last year with clinical development of its oral insulin, Biocon’s long hunt for a partner ends with Bristol-Myers Squibb, which signed a carefully worded “exclusive option agreement.”
Biologics Beckon: Biocon, Mylan Strike Deal; Combine To Take Teva, Sandoz Head-on
MUMBAI - Prospects for strong growth in the global generic biologics space in the next 10 years has brought together the world's third-largest generic drug maker Mylan and India's biotechnology company Biocon. The two signed a comprehensive deal that will share development and certain other costs to bring biologic drugs to the market